Table 6.
Overall evaluation of the tolerability of SQV 500 mg by analysis population, N (%)
| All Participants (N = 2122) | Treatment- Naïve (N = 413) | PI-Naïve but Treatment- Experienced (N = 265) | Toxicity Switch from Other PI Regimen (N = 161) | Toxicity Switch from Prior Non-PI Regimen (N = 201) | HCV Coinfection (N = 287) | Prior PI Regimen (N = 1386) | Prior Non-PI Regimen (N = 1640) | |
|---|---|---|---|---|---|---|---|---|
| Very good | 889 (41.9) | 162 (39.2) | 102 (38.5) | 83 (51.6) | 87 (43.3) | 196 (68.3) | 617 (44.5) | 715 (43.6) |
| Good | 535 (25.2) | 88 (21.3) | 68 (25.7) | 32 (19.9) | 47 (23.4) | 43 (15.0) | 375 (27.1) | 441 (26.9) |
| Sufficient | 90 (4.2) | 14 (3.4) | 8 (3.0) | 9 (5.6) | 6 (3.0) | 5 (1.7) | 66 (4.8) | 74 (4.5) |
| Insufficient | 35 (1.7) | 6 (1.5) | 4 (1.5) | 4 (2.5) | 5 (2.5) | 7 (2.4) | 25 (1.8) | 29 (1.8) |
| Cannot be evaluated | 110 (5.2) | 21 (5.1) | 18 (6.8) | 6 (3.7) | 13 (6.5) | 22 (7.7) | 70 (5.1) | 86 (5.2) |
| No information | 463 (21.8) | 122 (29.5) | 65 (24.5) | 27 (16.8) | 43 (21.4) | 14 (4.9) | 233 (16.8) | 295 (18.0) |
HCV = hepatitis C virus; PI = protease inhibitor; SQV = saquinavir.